Estimation of the Difference in Colistin Plasma Levels in Critically Ill Patients with Favorable or Unfavorable Clinical Outcomes

Estimation of the Difference in Colistin Plasma Levels in Critically Ill Patients with Favorable or Unfavorable Clinical Outcomes

In recent decades, antimicrobial resistance (AMR) has led to an increased use of therapeutic alternatives. Among these options, colistin continues to be an option for the treatment of multi-resistant (MDR) Gram-negative bacterial infections. However, due to its high toxicity (nephrotoxicity and neur...

Full description

Bibliographic Details
Main Authors: Jose Sanabria, Vivian Garzón, Tatiana Pacheco, Maria-Paula Avila, Julio-Cesar Garcia, Diego Jaimes, Angela Torres, Rosa-Helena Bustos, Javier Escobar-Perez, Deisy Abril
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Pharmaceutics
Subjects:
therapeutic drug monitoring (TDM)
colistin
multi-drug resistance bacteria
Gram-negative bacteria
Online Access:https://www.mdpi.com/1999-4923/13/10/1630

Internet

https://www.mdpi.com/1999-4923/13/10/1630

Similar Items